Nancye Sadler, NP
Addiction Medicine · Manassas, VANPI 1508818790
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 98.1% of the total across 149 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 25 manufacturers reported payments, led by AstraZeneca at 40.7% of the total. Reporting peaked in 2021 at $791 and has fallen 60.7% since, to $311 in 2025. Among addiction medicine clinicians in VA with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 149 payments — averaging $19.57 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$1K
- AbbVie$337
- Lilly USA, LLC$198
- Alkermes, Inc.$186
- Otsuka America Pharmaceutical, Inc.$143
- Indivior Inc.$110
- plus $755 from 19 others
What the payments were for
- Food & beverage$2,86098%
- Education$572%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca | 57 | $1,187 |
| AbbVie | 15 | $337 |
| Lilly USA, LLC | 11 | $198 |
| Alkermes, Inc. | 10 | $186 |
| Otsuka America Pharmaceutical, Inc. | 8 | $143 |
| Indivior Inc. | 6 | $110 |
| Exact Sciences | 4 | $107 |
| Novo Nordisk | 5 | $92 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 5 | $74 |
| Amgen | 3 | $67 |
| Avanir Pharmaceuticals, Inc. | 4 | $61 |
| Pfizer | 4 | $54 |
| Hikma Pharmaceuticals USA | 3 | $54 |
| Cumberland Pharmaceuticals, Inc. | 1 | $35 |
| Genentech USA, Inc. | 3 | $34 |
| Mylan Specialty L.p. | 1 | $23 |
| Organon | 1 | $23 |
| Johnson & Johnson | 1 | $22 |
| Merck | 1 | $18 |
| Bayer | 1 | $16 |
| Biohaven Pharmaceuticals, Inc. | 1 | $16 |
| GSK | 1 | $16 |
| Supernus Pharmaceuticals, Inc. | 1 | $15 |
| E.r. Squibb & Sons, L.L.C. | 1 | $15 |
| Currax Pharmaceuticals LLC | 1 | $15 |
How this compares
$2,916 in reported general payments places this provider in the 90th percentile of 44 addiction medicine providers in Virginia.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Other addiction medicine in Manassas
- Gerald LeeManassas$145
- Jeffrey KatraCharlottesville$59K
- Masaru NishiaokiVirginia Beach$6K
- Gene GermanoNorfolk$3K
- Mitchell BurkenFredericksburg$3K
- Gilbert SchmidtVirginia Beach$3K
- James GardnerRichmond$1K
- Joshua MoranNorfolk$1K
- Reymond Damasco PascualHampton$958
- Ronald MejzakVirginia Beach$618
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.